Ginkgo Bioworks, Inc.
Ginkgo Bioworks, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in cellular engineering, DNA sequencing, biointelligence, protein synthesis, pathogen detection, microbiome modulation, and biological manufacturing. Since its registration to receive federal awards in 2008, Ginkgo Bioworks has provided a wide range of research, testing, and production services to various U.S. government agencies, including the Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health. The company's work primarily focuses on developing innovative biotechnology solutions for defense, health, and energy applications. Ginkgo Bioworks leverages its expertise in synthetic biology to design and produce organisms, proteins, and other biological products for diverse industrial applications.
Through federal contracts, Ginkgo Bioworks has undertaken several significant projects for defense and civilian agencies. For the Defense Advanced Research Projects Agency (DARPA), the company has worked on developing solutions for extreme cold weather operational challenges (ICE Control for Cold Environments), immediate synthesis of bioactive protein medical countermeasures (Reimagining Protein Manufacturing program), and methods to modulate human skin microbiomes to reduce mosquito attraction (ReVector program). Ginkgo Bioworks has also provided critical services during the COVID-19 pandemic, including a $76.5 million contract with the CDC to conduct genomic testing and surveillance of SARS-CoV-2 at major U.S. international airports. Additionally, the company has worked on DNA recording for cellular biointelligence for the Naval Information Warfare Systems Command and provided COVID-19 saliva testing kits to the Air Force as a subcontractor to UES Inc. These contracts demonstrate Ginkgo Bioworks' versatility in applying its biotechnology expertise to various defense and public health challenges. Notably, most of these contracts were awarded without set-aside designations, indicating the company's competitive standing in the broader market.
Ginkgo Bioworks has also received several federal grants to support its research and development efforts. The U.S. Army awarded the company a $1.75 million cooperative agreement under the Basic Scientific Research program to advance foundational and applied research in areas such as cellular engineering and biological manufacturing. The Department of Energy provided a $1.36 million cooperative agreement for developing an integrated pest management approach to algal crop protection, supporting renewable energy research. The USDA's National Institute of Food and Agriculture granted nearly $650,000 for the Extensive Deer Genomic Surveillance (EDGES) project to study SARS-CoV-2 in farmed and wild deer populations. As a subgrantee, Ginkgo Bioworks has collaborated with Northeastern University on digital biointelligence tools for infectious disease monitoring, with Pennsylvania State University on model-guided animal prevalence surveillance, and with the Bioindustrial Manufacturing and Design Ecosystem on biodevelopment efforts. These grants showcase the company's involvement in diverse research areas, from agriculture and wildlife health to renewable energy and advanced materials.
Ginkgo Bioworks holds a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC) for test surge and data sharing services. This $118 million IDIQ, awarded in September 2024, has an ultimate completion date of September 5, 2029. Under this vehicle, Ginkgo Bioworks is expected to provide testing and data sharing capabilities to support the CDC's public health monitoring and emergency response initiatives. The contract leverages Ginkgo's expertise in biotechnology solutions, potentially building on their previous work with the CDC on COVID-19 genomic testing and surveillance. While specific task orders have not been detailed, this IDIQ positions Ginkgo Bioworks to continue providing critical biotechnology services to support the CDC's mission in protecting public health. The broad scope of this IDIQ underscores the government's recognition of Ginkgo Bioworks' capabilities in rapidly deploying advanced biotechnology solutions for public health challenges.
ZRHJUJQSBRA4 541714
Not listed 27 Drydock Ave #8, Boston, MA 02210, USA
8/18/08 1/20/26 Laboratory Corporation Of America
Laboratory Corporation of America, doing business as Labcorp, is a leading global life sciences company that provides comprehensive diagnostic testing services to the federal government. Through various contract vehicles, Labcorp offers a wide range of medical laboratory testing and analysis services to support government healthcare programs. The company operates a network of major clinical laboratories and specialized medical testing facilities, offering over 5,000 diagnostic tests and assay combinations. Labcorp's federal contracting activities primarily focus on providing reference laboratory testing, genomic screening, specimen transport, and connectivity services to agencies such as the Department of Veterans Affairs (VA), Defense Health Agency (DHA), Department of the Air Force, and Indian Health Service.
Labcorp has been awarded numerous prime federal contracts to deliver laboratory testing services across multiple agencies. For the VA, Labcorp provides reference laboratory testing to support Veterans Integrated Service Networks (VISNs) nationwide, with contract values ranging from small purchase orders to multi-million dollar requirements. The company also supports the DHA and various military branches by delivering clinical reference laboratory testing services at military treatment facilities, including Army medical centers, Air Force bases, and Naval hospitals. These contracts often involve comprehensive testing services for locations such as Fort Stewart, Lackland Air Force Base, and Tripler Army Medical Center. Labcorp's services extend to specialized testing, including autoimmune encephalopathy profiles, CMV resistance testing, and lipoprotein analysis. While most contracts are not set aside, Labcorp occasionally serves as a subcontractor to small businesses on federal projects.
Labcorp holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies. A key vehicle is the company's General Services Administration (GSA) Federal Supply Schedule contract for Medical Laboratory Testing and Analysis Services (FSS-621-II). This schedule allows various agencies to place orders for Labcorp's comprehensive testing services. The VA has awarded Labcorp multiple Blanket Purchase Agreements (BPAs) under this schedule, including a $3.5 million VISN-wide BPA for VISN 16, a $3.1 million BPA for the VA Portland Health Care System, and a $2.8 million BPA for emergency reference laboratory testing for VISN 2. These BPAs enable the VA to streamline procurement of specialized diagnostic services across its healthcare networks. Through these IDVs, Labcorp has received numerous firm-fixed-price task orders and BPA calls to provide diagnostic services at VA medical centers, supporting standardized laboratory testing and ensuring uninterrupted patient care services.
NHYWLYK6NBM8 621511
Not listed 231 Maple Ave, Burlington, NC 27215, USA
6/28/01 9/26/25 Arup Laboratories Inc.
Arup Laboratories Inc., doing business as Associated Regional And University Pathologists, is a not-for-profit clinical and anatomic pathology reference laboratory that provides specialized diagnostic, pathology, and laboratory testing services to the federal government through various contract and grant awards. As a subsidiary of the University of Utah, Arup Laboratories offers over 3,000 complex medical tests to healthcare facilities nationwide, leveraging its expertise in areas such as chemistry, microbiology, genetics, and immunology. The company serves as a major provider of reference laboratory services to federal agencies, particularly the Department of Veterans Affairs (VA) and the Defense Health Agency (DHA).
Through prime federal contract awards, Arup Laboratories has consistently delivered a wide range of laboratory testing services to support healthcare programs for veterans and other federal beneficiaries. The company has received numerous delivery orders and blanket purchase agreement calls from VA Veterans Integrated Service Networks (VISNs) across the country, providing reference laboratory testing for various medical centers and clinics. These contracts, often issued against Arup's GSA Federal Supply Schedule for Medical Laboratory Testing and Analysis Services, cover diverse testing needs including esoteric testing, clinical pathology, and specialized diagnostic services. Notable awards include multi-million dollar contracts with VISN 10, VISN 19, and VISN 21, demonstrating Arup's extensive involvement in supporting VA healthcare initiatives. Additionally, Arup has provided biomarker analysis services to the Department of Defense's Research, Development and Engineering Command, showcasing its capabilities beyond routine clinical testing.
In terms of federal grant awards, Arup Laboratories received a significant $15 million project grant from the U.S. Department of Health and Human Services under the Congressional Directives program (CFDA 93.493) in September 2023. This three-year grant, running through September 2026, funds specialized diagnostic, pathology, and laboratory testing services to support federal healthcare programs. While this represents a major prime grant award, Arup has also contributed to federal research initiatives as a sub-awardee. For instance, the company has provided subject matter expertise on inborn metabolism errors as part of a sub-award from the University of North Carolina at Chapel Hill for the Clinical Genome Resource project, which aims to advance genomic medicine through biocuration and expert assessment of genes and variants.
Arup Laboratories holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that facilitate efficient procurement of its services by government agencies. The company's primary vehicle is a Federal Supply Schedule contract (36F79720D0079) for Medical Laboratory Testing and Analysis Services, with a ceiling value of over $311 million and a performance period through March 2025. This schedule allows various agencies, particularly within the VA system, to issue delivery orders for a comprehensive range of laboratory services. Additionally, Arup holds multiple Blanket Purchase Agreements (BPAs) with different VA VISNs, including a $360 million agreement with VISN 21 (36F79720D0079|36C26120A0048) and a $5.7 million agreement with VISN 19 (36F79720D0079|36C25921A0031). These BPAs streamline the procurement process for recurring laboratory testing needs across multiple VA facilities. The company also maintains smaller IDVs, such as a $75,000 indefinite delivery contract with VISN 17 (36C25724D0043) for reference laboratory testing services. Through these vehicles, Arup Laboratories has positioned itself as a key provider of comprehensive laboratory services to the federal healthcare system, particularly in support of veterans' health initiatives.
NLTPT1KJARJ7 621511
Not listed 500 Chipeta Way, Salt Lake City, UT 84108, USA
4/23/02 10/10/25 Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, doing business as Quest Diagnostics, is a provider of diagnostic information services, providing clinical laboratory testing and analysis to support population health, precision medicine, and health plan operations. Through its nationwide network of laboratories, the company offers access to specialized diagnostic capabilities to federal agencies seeking to supplement in-house clinical testing resources.
Quest Diagnostics has provided a range of medical laboratory testing and analysis services to various federal agencies through prime contract awards over the past two years. This includes COVID-19 and other infectious disease testing valued up to $25 million for facilities under the Department of Justice's Bureau of Prisons and reference laboratory testing services worth over $2 million for the Department of Veterans Affairs' Veterans Integrated Service Network 12 to aid in caring for veterans. Additionally, Quest Diagnostics has provided specialized testing like blood specimen analysis and diagnostic screenings on a subcontractor basis to support population health initiatives for agencies such as the Centers for Disease Control and Prevention.
Under a sub-award from the University of California, San Francisco, Quest Diagnostics subsidiary ExamOne provided mobile phlebotomy services to collect and ship blood specimens for research through home visits. This supported a study on early biomarkers of Alzheimer's disease sponsored by the National Institutes of Health.
Several federal agencies have awarded indefinite delivery contracts to establish long-term vehicles for procuring clinical laboratory services on an as-needed basis from Quest Diagnostics, including Veterans Health Administration networks across different U.S. regions. For example, VISN 7 awarded a 5-year IDIQ valued up to $17.7 million for reference testing, while VISN 12 issued a 2-year IDIQ for similar services worth up to $6.1 million. Additionally, a 5-year, $51 million blanket purchase agreement was awarded by VISN 6 for reference laboratory testing and specimen transport support. Associated delivery orders and calls issued against these contract vehicles range from $80,000 to $2.4 million.
UC5SPMUJF8V3 621511
Not listed 500 Plaza Dr, Secaucus, NJ 07094, USA
4/16/02 5/28/25 Aegis Sciences Corporation
Aegis Sciences Corp (Aegis) is a forensic toxicology and healthcare laboratory that provides science-driven drug testing and consulting services. Aegis offers comprehensive drug testing solutions and toxicology services through its network of clinical laboratories.
Aegis has been awarded several prime federal contracts from agencies like the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) to provide COVID-19 testing, genomic sequencing, and variant tracking services. These firm fixed price contracts and purchase orders, ranging from $1.2 million to $39.9 million, task Aegis Analytical Laboratories to perform sequencing and testing out of its Nashville, Tennessee facility. Aegis also received a $17.98 million definitive contract under the RADx program to rapidly expand SARS-CoV-2 testing capacity over two years. No set-asides were used on these awards.
Aegis holds an indefinite delivery contract from the NIH National Heart, Lung and Blood Institute potentially valued at $47.97 million to provide viral variant genotyping through September 2027. Task Order 001 under this vehicle engages Aegis to conduct genotyping services from its Nashville laboratory between September 2022 and April 2024. Aegis also holds a 5-year Federal Supply Schedule contract authorizing Veterans Affairs sites to procure $40 million in medical laboratory testing from their catalog of clinical pathology services like hematology, immunology, and microbiology tests.
GJKTQDATP698 621511
Not listed 501 Great Circle Rd, Nashville, TN 37228, USA
3/31/03 7/24/25